Evidence map›Paper›PMID 39740005›Full record

ArticleEuropean journal of haematology2025

Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second Remission.

Avraham Frisch, Chezi Ganzel, Yishai Ofran, Baher Krayem, Arnon Haran, Vladimir Vainstein, Shlomzion Aumann, Noa Gross Even-Zohar, Boaz Nachmias

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Observational
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Avraham FrischDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, and Rappaport Faculty of Medicine-Technion, Haifa, Israel.
Chezi GanzelThe Hematology and Stem Cell Transplantation Department and the Eisenberg R&D Authority, Shaare Zedek Medical Center; Faculty of Medicine, Hebrew University of Jerusalem, Israel.ORCID https://orcid.org/0000-0002-1722-4807
Yishai OfranThe Hematology and Stem Cell Transplantation Department and the Eisenberg R&D Authority, Shaare Zedek Medical Center; Faculty of Medicine, Hebrew University of Jerusalem, Israel.
Baher KrayemDepartment of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, and Rappaport Faculty of Medicine-Technion, Haifa, Israel.
Arnon HaranDepartment of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel.
Vladimir VainsteinDepartment of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel.
Shlomzion AumannDepartment of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel.
Noa Gross Even-ZoharDepartment of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel.
Boaz NachmiasDepartment of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel.ORCID https://orcid.org/0000-0002-7341-2167

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular assessment of measurable residual disease (MRD) in NPM1-mutated AML patients is a powerful prognostic tool to identify the risk of relapse. There is limited data regarding MRD-guided decisions against alloSCT in elderly patients and FLT3-ITD co-mutation. We describe the outcome of NPM1-mutated AML patients in whom alloSCT was deferred based on ELN 2017 risk and MRD response. We report a relapse rate of 53% in this group, with a much higher incidence for older than 60 years patients than for younger patients (73% vs. 37%). When comparing outcomes of alloSCT in CR1 to intensive chemotherapy consolidation within each age group, patients over 60 years and patients with FLT3-ITD co-mutation had significantly lower RFS with intensive consolidation. Yet, in all subgroups, the lower RFS did not translate into OS difference, suggesting that relapsed NPM1 patients can often be salvaged and consequently achieve long-term remission. Our study supports the use of MRD response along with FLT3-ITD status in the decision to use post-remission therapy. We demonstrate that older patients and patients with FLT3-ITD-mutated AML have a high relapse rate but can be salvaged, leading to long-term survival.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteMutationNuclear ProteinsAdultAgedAged, 80 and overAge FactorsFemalefms-Like Tyrosine Kinase 3HumansMaleMiddle AgedNeoplasm, ResidualNucleophosminPrognosisFLT3 protein, humanfms-Like Tyrosine Kinase 3NPM1 protein, humanNuclear ProteinsNucleophosminAcute myeloid leukemiaMeasurable residual diseaseNPM1relapse

Identifiers

PMID39740005
PMCPMC11880982

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.